postmenopausal osteoporosis
Conditions
Interventions
Intervention group:Calcium intake was 1200mg(elemental calcium)/ day, calcitriol 0.25ug/ day, alendronate 70mg/ week, spironolactone 40mg/ day (orally divided twice). Patients with poor blood pressure
Control group:Calcium intake was 1200mg(elemental calcium)/ day, calcitriol 0.25ug/ day, alendronate 70mg/ week and CCB antihypertensive drugs were given to control blood pressure
Sponsors
Beijing Luhe Hospital, Capital Medical University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. To confirm the diagnosis of PMOP, the diagnostic criteria refer to the primary osteoporosis Diagnosis and Treatment Guidelines written by osteoporosis and Bone Mineral Salt Diseases Branch of Chinese Medical Association (2017). Bone mineral density of the central axis (lumbar 1-4, femoral neck or whole hip) or distal radius based on DXA measurements in postmenopausal women within 5-10 years. The diagnostic criteria for osteoporosis is t-score <= -2.5; 2. Clear history of hypertension (note: patients with spironolactone indication); 3. Female, aged 50-75; 4. Agree and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Definite diagnosis of primary aldosteronism; 2. secondary osteoporosis, including the influence of bone metabolic endocrine disease (parathyroid disease, gonad disease, adrenal disease, and thyroid disease, etc.), autoimmune diseases such as rheumatoid arthritis, and affecting the metabolism of calcium and vitamin absorption and digestive and kidney diseases, neuromuscular disease, malignant diseases such as multiple myeloma, A variety of congenital and acquired abnormal bone metabolism diseases, long-term use of glucocorticoids or other drugs affecting bone metabolism; 3. those with a life expectancy of less than 3 years; 4. Patients with serious heart, brain, liver and kidney diseases, tumors and kidney stones.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| dual energy X-ray absorptiometry; | — |
Secondary
| Measure | Time frame |
|---|---|
| ß-Collagen C-Telopeptide-x;Total Procollagen I N-Terminal Propeptide;glomerular filtration rate;serum potassium; | — |
Countries
China
Contacts
Public ContactNannan Wu
Beijing Luhe Hospital, Capital Medical University
Outcome results
None listed